Heterozygous mutations in SRSF2 occur in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and myeloproliferative neoplasm, which are related to poor prognosis. Here, SRSF2 is linked to myelodysplastic syndrome.